SH003 and Docetaxel Show Synergistic Anticancer Effects by Inhibiting EGFR Activation in Triple-Negative Breast Cancer

Abstract

Although many anticancer drugs have been developed for triple-negative breast cancer (TNBC) treatment, there are no obvious therapies. Moreover, the combination of epidermal growth factor receptor- (EGFR-) targeted therapeutics and classical chemotherapeutic drugs has been assessed in clinical trials for TNBC treatment, but those are not yet approved. Our serial studies for newly developed herbal medicine named SH003 provide evidence of its broad effectiveness in various cancers, especially on TNBC. The current study demonstrates a synergic effect of combinatorial treatment of SH003 and docetaxel (DTX) by targeting EGFR activation. The combinatorial treatment reduced the viability of both BT-20 and MDA-MB-231 TNBC cells, displaying the synergism. The combination of SH003 and DTX also caused the synergistic effect on apoptosis. Mechanistically, the cotreatment of SH003 and DTX inhibited phosphorylation of EGFR and AKT in both BT-20 and MDA-MB-231 cells. Moreover, our xenograft mouse tumor growth assays showed the inhibitory effect of the combinatorial treatment with no effect on body weight. Our immunohistochemistry confirmed its inhibition of EGFR phosphorylation in vivo. Collectively, combinatorial treatment of SH003 and DTX has a synergistic anticancer effect at a relatively low concentration by targeting EGFR in TNBC, indicating safety and efficacy of SH003 as adjuvant combination therapy with docetaxel. Thus, it is worth testing the combinatorial effect in clinics for treating TNBC.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Breast cancer is the leading cause of cancer-related death among women worldwide and has first surpassed lung cancer, with an estimated 2,261,419 new cases and 684,996 deaths in 2020 [1]. Breast cancer is commonly classified into three subtypes based on the expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Among these subtypes, triple-negative breast cancer (TNBC) is characterized by an absence of ER and PR and a lack of HER2 overexpression. Although other breast cancer subtypes including ER+/PR+/HER2-, ER+/PR-/HER2-, and HER2 overexpression have been managed by targeted therapy such as endocrine therapy and anti-HER2 therapy with improved prognosis, there are no effective therapeutic ways for TNBC [2–4].

Epidermal growth factor receptor (EGFR) suffers autophosphorylation at multiple tyrosine residues via its interaction with its endogenous ligand and activates downstream signaling pathways including ERK, AKT, and STAT3 [5]. Therefore, EGFR-mediated events are multifaceted in the cells. EGFR is overexpressed in TNBC, thereby being proposed as a therapeutic target [6]. While BRCA mutation appears to be linked to EGFR overexpression in TNBC, underlying mechanisms are still unclear [7, 8]. Moreover, gain-of-function mutations of EGFR are not broadly detected in TNBC patients [9]. EGFR-targeting agents such as gefitinib, erlotinib, osimertinib, and cetuximab are often used in clinics. Although EGFR-targeting agents are currently approved for nonsmall cell lung cancer (NSCLC) on the basis of their effectiveness, the response is limited to patients with gain-of-function mutations of EGFR such as exon 19 deletion and L858R mutation [10]. Those agents are not working in NSCLC with wild-type EGFR overexpression, which is a reason that those agents fail in TNBC treatment even though molecular and cellular mechanisms are completely unclear [11–13]. Nevertheless, clinical trials evaluating the effect of EGFR-targeting agents in combination therapies with chemotherapies are still conducted for TNBC treatment [14].

Docetaxel (DTX), a semisynthetic analog of paclitaxel isolated from European yew (Taxus baccata), is one of chemotherapeutics that causes cell cycle arrest by interfering with microtubules functions [15, 16]. DTX was first approved for the treatment of cancer such as breast, ovarian, and nonsmall cell lung cancer, and especially used in treatment of TNBC or early stage of human breast cancers [17]. Even though DTX is the effective anticancer drug, most chemotherapeutic agents including DTX have faced to limitations such as drug resistance, cancer recurrence, and adverse effects [18, 19]. Therefore, it is urgent to enhance the effectiveness of DTX in TNBC treatment with no adverse effect. One of therapeutic ways is likely to reduce its dose, which could ameliorate adverse effects with keeping its effectiveness.

SH003 is an herbal mixture consisting three herbs Astragalus membranaceus (Am), Angelica gigas (Ag), and Trichosanthes Kirilowii Maximowicz (Tk), which has been developed as a novel anticancer drug against several cancers including prostate, cervical, pancreatic, and breast cancer [20–22]. Especially, SH003 inhibits the growth of MDA-MB-231 TNBC cell line by inducing apoptosis followed by autophagy, both in vitro and in vivo [23]. Moreover, a combination of SH003 and doxorubicin exhibits synergistic effect on TNBC [24]. In addition, SH003 sensitizes paclitaxel-resistant ER-positive MCF7 cells to paclitaxel by inhibiting p-glycoprotein (MDR1) activity [25]. Based on the chemotherapeutic effect of SH003 or DTX on TNBC, we hypothesized that SH003 treatment combined with DTX may be effective for treatment of TNBC.

The present study is aimed at evaluating the synergistic effect of SH003 and DTX in TNBC cells. We showed that cotreatment of SH003 and DTX synergistically enhances apoptotic cell death in BT-20 and MDA-MB-231 cells. Both in vitro and in vivo studies demonstrated that blocking EGFR signaling is a key in the inhibitory mechanism of combination therapy. These findings suggest that combination of SH003 and DTX would be one of beneficial therapeutic strategy for TNBC treatment.

2. Materials and Methods

2.1. SH003, Chemicals, and Reagents

SH003 was prepared as described in our previous study [26]. In brief, SH003 was provided from Hanpoong Pharm and Foods Company (Jeonju, Republic of Korea). Am, Ag, and TK were mixed at 1 : 1 : 1 ratio ($w/w$) and then extracted with 30% ethanol at 100°C for 3 h. Dried extracts were dissolved in 30% ethanol and stored at −80°C until use. DTX (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in DMSO and stored at −20°C.

Thiazolyl blue tetrazolium bromide (MTT) powder was purchased from Sigma-Aldrich (St. Louis, MO, USA). FITC-conjugated Annexin V apoptosis Detection Kit and 7-aminoactinomycin D (7-AAD) were purchased from BD Pharmingen™ (BD Biosciences, San Jose, CA, USA) and Sigma-Aldrich (St. Louis, MO, USA), respectively. Anticleaved caspase-3, -PARP, -GAPDH, -p-EGFR (Tyr 1068), -p-EGFR (Tyr 1173), -EGFR, -p-AKT (Ser 473), -AKT, -p-C-Raf (Ser 338), -p-STAT3, and -STAT3 antibodies were purchased from Cell Signaling (Danvers, MA, USA). Anti-p-ERK and ERK antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Ki67 and CD31 antibodies were purchased from Abcam (Cambridge, MA, USA). Horseradish peroxidase- (HRP-) conjugated secondary antibodies for mouse and rabbit were purchased from SeraCare Life Sciences (Milford, MA, USA).

2.2. Cell Culture

Human breast cancer BT-20 and MDA-MB-231 cell lines were purchased from Korean Cell Line Bank (Seoul, Republic of Korea) and cultured in DMEM or RPMI-1640 medium (WelGENE, Daegu, Republic of Korea) supplemented with 10% fetal bovine serum (JR Scientific, Inc., Woodland, CA, USA) and 1% penicillin/streptomycin solution (WelGENE, Daegu, Republic of Korea). The cells were maintained at 37°C in 5% CO₂/95% air with 100% humidity.

2.3. MTT Assay and Combination Index Analysis

BT-20 and MDA-MB-231 cells were seeded in 96-well plates and then treated with SH003 (100, 300, and 500 μg/mL), DTX (1, 10, 100, and 1000 nM), or combination. After 24 h incubation, cell viability was measured by MTT assay with an absorbance at 570 nm. The interaction (synergistic, additive, and antagonistic effects) between SH003 and DTX was assessed by combination index (CI) analysis using Compusyn software (ComboSyn, Inc., Paramus, NJ, USA) (http://www.combosyn.com). CI value was calculated by the equation as follows [27]: $$\begin{array}{}\text{(1)}& C{I}_x=\frac{D_1}{{D_x}_1}+\frac{D_2}{{D_x}_2}\end{array}$$

${D_x}_1$ is the dose of SH003 alone that inhibits ${}_{\text{x}}\%$. ${D_x}_2$ is the dose of DTX alone that inhibits ${}_{\text{x}}\%$. $D_1$ the portion of SH003 in combination SH003 and DTX also inhibits ${}_{\text{x}}\%$. $D_2$ is the portion of DTX in combination SH003 and DTX also inhibits ${}_{\text{x}}\%$. “$CI<1$”, “$CI=1$”, and “$CI>1$” mean synergistic, additive, and antagonistic effect, respectively.

2.4. Apoptosis Analysis by Flow Cytometry

Apoptotic cell death was analyzed by Annexin V/7-AAD double staining. Cells were stained with Annexin V followed by staining with 7-AAD in the dark for 15 min at room temperature. Stained cells were detected by FACSCalibur (BD Biosciences, San Jose, CA, USA), and apoptotic cells were analyzed using CellQuest Pro version 5.2 (BD Biosciences, San Jose, CA, USA) software.

2.5. TUNEL Assay

DNA fragmentation was measured using TUNEL assay (Abcam, Cambridge, MA, USA), according to the manufacturer’s protocol. After the treatment with SH003, DTX, or combination for 24 h, the cells were harvested and fixed in 4% paraformaldehyde (PFA) for 15 min at 4°C. The cells were washed with PBS, resuspended in 100 μL of PBS, and then added 1 mL of 70% EtOH for 30 min on ice. Subsequently, the cells were washed twice in wash buffer and incubated with 50 μL of DNA labeling solution containing TdT enzyme and Br-dUTP for 1 h at 37°C. The cells were added rinse buffer and centrifuged. Then, the samples were resuspended in 50 μL of anti-BrdU-Red antibody solution for 30 min at room temperature in the dark. Stained cells were diluted with rinse buffer and analyzed in FL-2 channel by flow cytometry.

2.6. Transfection

Cells were seeded in 6-well plate and transfected with 1.5 μg pCDNA3-Myr-HA-AKT2 (addgene #9016) plasmid using lipofectamine 3000 (Invitrogen, CA, USA). Cells were incubated in 10% FBS/antibiotic-free media for 24 h and then trypsinized and seeded for additional studies.

2.7. Western Blotting

Total protein was extracted with RIPA buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% triton X-100, 2 mM EDTA, 0.1% SDS, and 1% sodium deoxycholate. Protein concentration was quantified by Bradford assay, and proteins were separated on 8-12% SDS-PAGE. Separated proteins were transferred to nitrocellulose membrane and blocked with 5% skim milk in PBS-T at room temperature for 1 h. The membrane was incubated with primary antibodies at 4°C overnight, washed, and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h. Proteins were measured using the EZ-western detection kit (Dogen-Bio, Seoul, Republic of Korea).

2.8. In Vivo Studies

All animal studies were approved by Kyung Hee University Institutional Animal Care and Use Committee (KHU-IACUC). Five-week-old female BALB/c nude mice were purchased from Nara Biotech (Seoul, Republic of Korea). Mice were given to access to food and drinking water ad libitum and were housed in appropriate isolated cage under pathogen-free condition with 12 h light/12 h dark cycle at room temperature (22-25°C). To establish tumor xenograft mouse model, BT-20 cell suspension ($1\times {10}^7$ cells) in 100 μL PBS was subcutaneously inoculated in the right flank of mice. Based on no observed adverse effect of levels (NOAEL) of SH003 from phase 1 clinical study (4,800 mg/day) and maximum tolerable dose of DTX (75 mg/m²) in cancer patients (NCT03081819) [28], animal equivalent dose was determined by following equation: $\text{Human}\text{equivalent}\text{dose}\text{mg}/\text{kg}=\text{Animal}\text{dose}\text{mg}/\text{kg}\ast {\text{Weigh}{\text{t}}_{\text{animal}}\text{kg}/\text{Weigh}{\text{t}}_{\text{human}}\text{kg}}^{1-0.75}$ [29]. Human and mice weights are 65 kg and 0.02 kg, respectively. Based on Kleiber’s law [30], exponent for body surface area is 0.75, which account for difference in metabolic rate. Mice were divided into four groups; control ($n=3$), SH003 ($n=4$), DTX ($n=4$), and $\text{SH}003+\text{DTX}$ ($n=5$). When tumor volume reached at 100 mm³, drugs were injected. DTX was administrated intravenously via tail vein once a week with 15.277 mg/kg, while DMSO to control or SH003 alone group. SH003 was orally treated three times a week with 557.569 mg/kg, while saline to control or DTX alone group. Body weights were measured three times a week, and tumor volumes were analyzed daily for 17 days. Tumor volume was calculated using the formula: $\text{widt}{\text{h}}^2\times \text{length}/2$. The mice were euthanized, and tumors were isolated. Tumor tissues were fixed and embedded in paraffin. For hematoxylin and eosin (H & E) staining, tissues mounted on slide glasses were incubated with H & E solution. The immunohistochemical analysis was performed using Vectastain ABC-AP staining kit according to manufacturer’s instruction (Vector Laboratories, Burlingame, CA USA). The slide was stained with Ki-67, CD31, p-EGFR (Tyr 1068), and cleaved caspase-3 after performing heat-induced antigen retrieval using sodium citrate buffer (pH 6.0). Images of H & E and IHC were obtained with microscope (Carl Zeiss, Germany) at a magnification of 40×.

2.9. Statistical Analysis

Data were shown as the mean and standard deviation from at least three experiments. The statistical differences of means among the groups were analyzed by one-way ANOVA followed by Dunnett’s or Bonferroni’s test. $P$ value < 0.05 means statistically significant differences.

3. Results

3.1. Synergistic Effect of SH003 and DTX on TNBC Cell Viability

We first investigated the cytotoxic effect on TNBC cells by either SH003 or DTX. BT-20 and MDA-MB-231 cells were exposed to various concentrations of either SH003 or DTX for 24 h. SH003 did not affect the viabilities of both BT-20 and MDA-MB-231 cells, as the viabilities were about 83% and 98% at 500 μg/mL dose, respectively (Figures 1(a) and 1(b)). However, DTX decreased the viabilities of both BT-20 and MDA-MB-231 cells in a dose-dependent manner (Figures 1(c) and 1(d)). Moreover, cotreatment of SH003 with DTX significantly inhibited the viability of TNBC cells, although not show a dose-dependent effect in cell survival (Figures 1(e) and 1(f)). To identify whether SH003 has the synergistic effect with DTX, the combination index (CI) value of drug pair was evaluated (Tables 1 and 2).

[figure(s) omitted; refer to PDF]

Table 1

Combination index value of SH003 and DTX in BT-20 cells.

Drug		BT-20
DTX (nM)	SH003 (μg/mL)	Combination index (CI)
1	100	0.44311
	300	0.70508
	500	1.14198
10	100	0.23670
	300	0.70086
	500	1.14927
100	100	0.35019
	300	1.05284
	500	1.57479
1000	100	1.12051
	300	4.74933
	500	10.8015

Table 2

Combination index value of SH003 and DTX in MDA-MB-231 cells.

Drug		MDA-MB-231
DTX (nM)	SH003 (μg/mL)	Combination index (CI)
1	100	1.85E20
	300	5.90E23
	500	7.01930
10	100	3.82112
	300	3.16236
	500	1.17233
100	100	0.09965
	300	0.27457
	500	0.42340
1000	100	0.19020
	300	0.45114
	500	0.57037

The highest synergistic effects in BT-20 and MDA-MB-231 cells were observed in combination of SH003 at 100 μg/mL and DTX at 10 nM (CI: 0.24) and in combination of SH003 at 100 μg/mL and DTX at 100 nM (CI: 0.1), respectively (Figures 1(e) and 1(f)). These findings indicated that SH003 and DTX have the synergistic effect at a relatively low concentration of DTX by blocking excessive toxicity accumulation.

3.2. Combination of SH003 and DTX Induces the Apoptotic Cell Death

To examine apoptosis, BT-20 and MDA-MB-231 cells were treated with SH003 and/or DTX for 24 h, and then apoptosis was analyzed by flow cytometry. In Figures 2(a) and 2(b), the results showed that combined with SH003 and DTX induces apoptosis in both cells. In BT-20 cells, the combinatorial treatment enhanced the level of the early and late apoptotic cells, compared with SH003 or DTX alone (Figure 2(a)). Similarly, the combination of SH003 and DTX increased levels of cleaved PARP and cleaved caspase-3, which is known to marker of early apoptosis processes (Figure 2(c)). As shown in Figure 2(b), we observed that the cotreatment showed a similar increase in the early and late apoptotic cells (about 24%) with DTX (about 23%), while the increase in late apoptotic cells was higher in combinatorial treatment than in DTX. Also, apoptosis markers were induced by both DTX and cotreatment (Figure 2(d)). These results suggest that apoptosis process in MDA-MB-231 is distinct from BT-20. Therefore, we further performed the TUNEL assay to assess the induction of late apoptosis by combination treatment in MDA-MB-231 cells. The TUNEL assay can detect the DNA fragmentation, which is a representative marker occurred in end process of apoptosis [31, 32]. In BT-20 cells, SH003, DTX, and combination treatment increased the TUNEL positive cells, but there was no synergistic effect of combination treatment. On the other hand, the combination of SH003 and DTX caused an increase in TUNEL positive cells (about 10%) than DTX single (about 6%) in MDA-MB-231 cells (Figure 2(e)), indicating that combination treatment synergistically induces apoptotic cell death and especially is mediated by late apoptosis process in MDA-MB-231 cells and early/middle apoptosis in BT-20 cells. Taken together, these results demonstrated that combination treatment promotes the sensitivity of SH003 or DTX on TNBC cell by increasing the apoptosis.

[figure(s) omitted; refer to PDF]

3.3. SH003 Combined with DTX Induces Apoptosis through EGFR-AKT Signaling Pathway

EGFR is overexpressed in TNBC cells [6], and EGFR-targeted therapeutics have been developed for treatment [33]. Therefore, we investigated if the combination of SH003 and DTX inhibits EGFR signaling pathway. As shown in Figures 3(a) and 3(b), combinatorial treatment of SH003 and DTX inhibited phosphorylation of EGFR in both BT-20 and MDA-MB-231 cells. AKT, Raf/ERK, and STAT3 are downstream signaling factors of EGFR-mediated signaling and known to activate tumor growth and metastasis [34]. Furthermore, many studies have been focused on AKT, ERK, and STAT3 as therapeutic targets in TNBC cells [35–37]. Therefore, we assessed whether combination of SH003 and DTX regulates downstream pathway of EGFR. Compared with SH003 or DTX alone, combinatorial treatment decreased phosphorylation of AKT in both BT-20 and MDA-MB-231 cells. However, the combinatorial treatment inhibited phosphorylation of Raf/ERK and STAT3 only in BT-20 cells (Figures 3(c) and 3(d)), suggesting that molecular module of EGFR-mediated downstream signaling may be different between BT-20 and MDA-MB-231 cells.

[figure(s) omitted; refer to PDF]

Next, we examined whether inhibited EGFR-AKT signaling pathway is directly related to cell death mechanism by combinatorial treatment. Upon epidermal growth factor (EGF) binds to EGFR, it activates AKT-mediated cancer cell proliferation and metastasis. As shown in Figure 4(a), the effect of combination was blocked by EGF treatment in two breast cancer cells. EGF treatment abolished the EGFR and AKT inactivation by combination treatment, but also increased apoptosis markers were inhibited by EGF (Figures 4(b) and 4(c)). Also, EGF rescued both BT-20 and MDA-MB-231 cells from the apoptosis induction by SH003 and DTX (Figure 4(d)), suggesting the inhibition of EGFR signaling involved in apoptotic cell death and AKT inhibition by the combined treatment. We then found the effect of downstream AKT on breast cancer cell death. In Figure 4(e), when AKT was overexpressed, the combination of SH003 and DTX increased the cell viability compared to the control group in BT-20 and MDA-MB-231 cells. In addition, AKT-overexpressed cells prevented the cleavage of PARP, an apoptotic marker, under combination treatment (Figures 4(f) and 4(g)). Based on these results, we suggest that EGFR-AKT pathway is likely to be the main targets of SH003-DTX combination treatment on breast cancer.

[figure(s) omitted; refer to PDF]

3.4. Combination with SH003 and DTX Suppresses the Tumor Growth and EGFR Phosphorylation In Vivo

To investigate the efficacy of SH003 combined with DTX in vivo, we observed antitumor effect in BT-20 breast cancer xenograft mouse model. Combinatorial treatment of SH003 (557.57 mg/kg) and DTX (15.28 mg/kg) most effectively suppressed tumor growth (Figure 5(a)). Consistently, the combinatorial treatment reduced tumor weight and size (Figure 5(b)). However, those drugs did not affect body weight (Figure 5(c)).

[figure(s) omitted; refer to PDF]

Our immunohistochemistry confirmed that the combinatorial treatment effectively blocked tumor growth, as it reduced Ki67-positive cell numbers but increased cleaved caspase-3-positive cell numbers (Figure 6, second and third rows). Accordingly, the combinatorial treatment reduced CD31-positive cell numbers (Figure 6, the fourth row). Moreover, the combinatorial treatment reduced the number of cells expressing EGFR phosphorylation at Tyr 1068 (Figure 6, the fifth row).

[figure(s) omitted; refer to PDF]

4. Discussion

Although DTX has been used in treatment of many cancer patients, high dose of DTX induces severe side effects including anemia, peripheral neuropathy, and nausea. Moreover, low sensitivity and acquired drug resistance of DTX are still problems [38, 39]. For enhancing the effectiveness of DTX, studies about the combination therapy have been investigated in clinical models, especially in TNBC patients [40, 41]. In this study, we evaluated the synergistic effect of SH003 and DTX in TNBC cell lines and found that SH003 enhances the anticancer effect of DTX by inducing apoptosis and inhibiting the EGFR-AKT signaling pathway of TNBC in vitro and in vivo with no adverse effect (Figure 7).

[figure(s) omitted; refer to PDF]

In combination therapeutics with synthetic drugs, role of natural products is highly significant due either to a promotion in bioavailability and to a reduction of drug dose via synergistic effect [42]. Natural agents such as curcumin, 20S-protopanaxadiol, and flavonoids showed the combination effect with anticancer drugs by inhibiting cell proliferation or drug resistance mechanisms in breast cancer cells [43–45]. We have reported that SH003 has the anticancer effect and also synergistic effect with chemotherapy in TNBC [20, 24, 26]. Thus, the present study is aimed at determining the highest effective dose of SH003 and DTX which has the synergistic effect against TNBC.

Combination therapy is the result of drug interactions, and it is important to find effective drug pairs. In particular, response rates to anticancer drugs in cancer cells could be different because of cancer heterogeneous characteristics, so an appropriate target dose of each drug in combination regimen should be determined. In addition, in order to apply to patients, it is necessary to determine the optimal combination dose through clinical trials [46]. Our results indicated the drug synergism at lower concentrations of SH003 and DTX in vitro, but this synergistic effect did not increase at higher concentrations of SH003. In particular, high dose of SH003 showed antagonistic action in BT-20 cells. But we observed that the combination therapy had antitumor efficacy at the dose used in clinical trial. By using the concentrations of DTX (75 mg/m2) and SH003 (4800 mg/65 kg) determined by MTD and NOAEL studies, we validated the tumor suppression effect of combination treatment, minimizing the side effects in BT-20 cells. These results suggest that clinical studies should be conducted to find an appropriate dose combination regimen that works synergistically while reducing possible side effects. Thus, we demonstrated that SH003 can be a potential agent for combinatorial therapy with DTX, expecting to minimize DTX toxicity in clinical use.

Because high level of EGFR is discovered in about 40% of TNBC, EGFR is a promising target for treatment of TNBC. EGFR-targeted therapy has been developed and used to study for TNBC treatment. Currently, clinical trials of DTX combined with anti-EGFR antibody are ongoing in TNBC patients (NCT01939054) [47]. Although many clinical trials have attempted EGFR-targeting therapies in patient with TNBC subtype, most patients indicated no significant differences in overall response rate [6]. In case of NSCLC treatments, wild-type EGFR NSCLC patients also have low response to EGFR-TKI (tyrosine kinase inhibitors) treatment due to EGFR-TKIs are mostly effective in NSCLC harboring EGFR activating mutations [48]. These results suggest that the development of novel therapeutics targeting wild-type EGFR can overcome failure of EGFR-TKI therapy in TNBC [49]. Our study demonstrated that combinatorial treatment of SH003 and DTX significantly suppresses phosphorylation of EGFR in vitro and in vivo model. Thus, we suggest that this combinatorial treatment may be an effective therapy for wild-type EGFR amplified TNBC. Further studies are needed to confirm if SH003 and DTX treatment improves EGFR-TKI sensitivity in wild-type EGFR TNBC.

Many studies have shown that the dysregulation of EGFR signaling pathways including AKT, ERK and STAT3 is associated with tumor proliferation and survival [50–52]. Oncogenic function of these pathways contributes to chemoresistance and metastasis in TNBC and thus has been regarded as potential therapeutic targets [37, 53, 54]. We demonstrated that the combinatorial treatment induces apoptotic cell death by suppressing the activation of AKT in both BT-20 and MDA-MB-231 cells. SH003 combined with DTX significantly inhibited ERK and STAT3 phosphorylation in BT-20 cells while activity of ERK and STAT3 is not changed in MDA-MB-231 cells. In the recent study, it was reported that ERK is constitutively activated in MDA-MB-231 cells when compared with BT-20 cells [55]. Also, the expression of STAT3 protein was similar in BT-20 and MDA-MB-231 cells, but a level of STAT3 phosphorylation showed relatively low activity in MDA-MB-231 cells. These diversities of STAT3 activity can be caused by protein expression of ErbB family members as STAT3 upstream pathway [56]. In the therapy of cancer patients through EGFR inhibition, it has been reported that the regulation of the EGFR downstream proteins is important to determine the clinical response [57–59]. Taken together, the different response to combinatorial treatment in both cell lines can be explained by cell line-specific genetic characters. These results can support our finding that the combinatorial treatment more effectively inhibits the proliferation of BT-20 cells at low dose compared with MDA-MB-231 cells. In addition, it can be considered as a biomarker to determine the efficacy and reactivity of drugs depending on which EGFR downstream signaling is regulated.

5. Conclusions

The present study suggests that DTX in combination with SH003 would be a good strategy to treat TNBC patients. Furthermore, this combination reduced the EGFR activity and its downstream AKT signaling pathway as a major treatment target for EGFR-amplified TNBC. According to these observations, we also suggest that combination treatment of SH003 and DTX is possible to be considered as an effective drug combination strategy for the treatment of patients with TNBC.

Authors’ Contributions

Y.J.C. and K.L. designed and carried out the experiments and drafted and revised the manuscript. S.G.C. participated in its design and revised the manuscript. J.H.Y., Y.G.K., M.J., H.H.H., S.Y.L., and S.E.J. performed experiments and data analysis. S.G.K. did the supervision and conceptualization. Yu-Jeong Choi and Kangwook Lee contributed equally to this work.

Acknowledgments

This study was supported by the Korean Medicine R & D Project of the Ministry of Health and Welfare (Grant number: HI18C2382) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (Grant number: 2020R1A5A2019413).

Glossary

Abbreviations

TNBC:Triple-negative breast cancer

DTX:Docetaxel

CI:Combination index

Am:Astragalus membranaceus

Ag:Angelica gigas

Tk:Trichosanthes Kirilowii Maximowicz

EGFR:Epidermal growth factor receptor

TKI:Tyrosine kinase inhibitor.

References

[1] H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: a Cancer Journal for Clinicians, vol. 71 no. 3, pp. 209-249, DOI: 10.3322/caac.21660, 2021.

[2] P. Kumar, R. Aggarwal, "An overview of triple-negative breast cancer," Archives of Gynecology and Obstetrics, vol. 293 no. 2, pp. 247-269, DOI: 10.1007/s00404-015-3859-y, 2016.

[3] O. Engebraaten, H. K. M. Vollan, A. L. Borresen-Dale, "Triple-negative breast cancer and the need for new therapeutic targets," The American Journal of Pathology, vol. 183 no. 4, pp. 1064-1074, DOI: 10.1016/j.ajpath.2013.05.033, 2013.

[4] J. R. Jhan, E. R. Andrechek, "Triple-negative breast cancer and the potential for targeted therapy," Pharmacogenomics, vol. 18 no. 17, pp. 1595-1609, DOI: 10.2217/pgs-2017-0117, 2017.

[5] P. Wee, Z. Wang, "Epidermal growth factor receptor cell proliferation signaling pathways," Cancers (Basel), vol. 9 no. 5,DOI: 10.3390/cancers9050052, 2017.

[6] K. Nakai, M. C. Hung, H. Yamaguchi, "A perspective on anti-EGFR therapies targeting triple-negative breast cancer," American Journal of Cancer Research, vol. 6 no. 8, pp. 1609-1623, 2016.

[7] L. N. Burga, H. Hu, A. Juvekar, N. M. Tung, S. L. Troyan, E. W. Hofstatter, G. M. Wulf, "Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice," Breast Cancer Research, vol. 13 no. 2,DOI: 10.1186/bcr2850, 2011.

[8] B. Nisman, L. Kadouri, T. Allweis, B. Maly, T. Hamburger, S. Gronowitz, T. Peretz, "Increased proliferative background in healthy women withBRCA1/2Haploinsufficiency is associated with high risk for breast cancer," Cancer Epidemiology, Biomarkers & Prevention, vol. 22 no. 11, pp. 2110-2115, DOI: 10.1158/1055-9965.EPI-13-0193, 2013.

[9] H. S. Park, M. H. Jang, E. J. Kim, H. J. Kim, H. J. Lee, Y. J. Kim, J. H. Kim, E. Kang, S. W. Kim, I. A. Kim, S. Y. Park, "High _EGFR_ gene copy number predicts poor outcome in triple-negative breast cancer," Modern Pathology, vol. 27 no. 9, pp. 1212-1222, DOI: 10.1038/modpathol.2013.251, 2014.

[10] R. Shah, J. F. Lester, "Tyrosine kinase inhibitors for the treatment of _EGFR_ mutation-positive non -small-cell lung cancer: a clash of the generations," Clinical Lung Cancer, vol. 21 no. 3, pp. e216-e228, DOI: 10.1016/j.cllc.2019.12.003, 2020.

[11] A. Kim, M. H. Jang, S. J. Lee, Y. K. Bae, "Mutations of the epidermal growth factor receptor gene in triple-negative breast cancer," Journal of Breast Cancer, vol. 20 no. 2, pp. 150-159, DOI: 10.4048/jbc.2017.20.2.150, 2017.

[12] M. Itchins, S. Clarke, N. Pavlakis, "Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics," Translational Lung Cancer Research, vol. 7 no. S1, pp. S39-S45, DOI: 10.21037/tlcr.2018.01.06, 2018.

[13] T. E. Stinchcombe, "The use of EGFR tyrosine kinase inhibitors in EGFR wild-type non-small-cell lung cancer," Current Treatment Options in Oncology, vol. 17 no. 4,DOI: 10.1007/s11864-016-0394-4, 2016.

[14] L. Carey, E. Winer, G. Viale, D. Cameron, L. Gianni, "Triple-negative breast cancer: disease entity or title of convenience?," Nature Reviews Clinical Oncology, vol. 7 no. 12, pp. 683-692, DOI: 10.1038/nrclinonc.2010.154, 2010.

[15] J. Gligorov, J. P. Lotz, "Preclinical pharmacology of the taxanes: implications of the differences," The Oncologist, vol. 9,DOI: 10.1634/theoncologist.9-suppl_2-3, 2004.

[16] J. A. Yared, K. H. Tkaczuk, "Update on taxane development: new analogs and new formulations," Drug Design, Development and Therapy, vol. 6, pp. 371-384, DOI: 10.2147/DDDT.S28997, 2012.

[17] M. Y. Ho, J. R. Mackey, "Presentation and management of docetaxel-related adverse effects in patients with breast cancer," Cancer Management and Research, vol. 6, pp. 253-259, DOI: 10.2147/CMAR.S40601, 2014.

[18] J. J. Tao, K. Visvanathan, A. C. Wolff, "Long term side effects of adjuvant chemotherapy in patients with early breast cancer," Breast, vol. 24, pp. S149-S153, DOI: 10.1016/j.breast.2015.07.035, 2015.

[19] K. D. Miller, L. Nogueira, A. B. Mariotto, J. H. Rowland, K. R. Yabroff, C. M. Alfano, A. Jemal, J. L. Kramer, R. L. Siegel, "Cancer treatment and survivorship statistics, 2019," CA: a Cancer Journal for Clinicians, vol. 69 no. 5, pp. 363-385, DOI: 10.3322/caac.21565, 2019.

[20] E. K. Choi, S. M. Kim, S. W. Hong, J. H. Moon, J. S. Shin, J. H. Kim, I. Y. Hwang, S. A. Jung, D. H. Lee, E. Y. Lee, S. Lee, H. Kim, D. Kim, Y. S. Kim, Y. K. Choi, H. I. Kim, H. S. Choi, S. G. Cho, J. E. Kim, K. P. Kim, Y. S. Hong, W. K. Lee, J. S. Lee, T. W. Kim, S. G. Ko, D. H. Jin, "SH003 selectively induces p73-dependent apoptosis in triple-negative breast cancer cells," Molecular Medicine Reports, vol. 14 no. 4, pp. 3955-3960, DOI: 10.3892/mmr.2016.5722, 2016.

[21] Y. J. Choi, Y. K. Choi, K. M. Lee, S. G. Cho, S. Y. Kang, S. G. Ko, "SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway," BMC Complementary and Alternative Medicine, vol. 16 no. 1,DOI: 10.1186/s12906-016-1490-5, 2016.

[22] H. S. Choi, M. K. Kim, K. Lee, K. M. Lee, Y. K. Choi, Y. C. Shin, S. G. Cho, S. G. Ko, "SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2," Oncotarget, vol. 7 no. 22, pp. 32969-32979, DOI: 10.18632/oncotarget.8808, 2016.

[23] Y. K. Choi, S. G. Cho, Y. J. Choi, Y. J. Yun, K. M. Lee, K. Lee, H. H. Yoo, Y. C. Shin, S. G. Ko, "SH003 suppresses breast cancer growth by accumulating p 62 in autolysosomes," Oncotarget, vol. 8 no. 51, pp. 88386-88400, DOI: 10.18632/oncotarget.11393, 2017.

[24] S. M. Woo, A. J. Kim, Y. K. Choi, Y. C. Shin, S. G. Cho, S. G. Ko, "Synergistic effect of SH003 and doxorubicin in triple-negative breast cancer," Phytotherapy Research, vol. 30 no. 11, pp. 1817-1823, DOI: 10.1002/ptr.5687, 2016.

[25] H. S. Choi, S. G. Cho, M. K. Kim, H. J. Lee, S. H. Moon, H. J. Jang, S. G. Ko, "SH003 enhances paclitaxel chemosensitivity in MCF-7/PAX breast cancer cells through inhibition of MDR1 activity," Molecular and Cellular Biochemistry, vol. 426 no. 1-2,DOI: 10.1007/s11010-016-2875-y, 2017.

[26] Y. K. Choi, S. G. Cho, S. M. Woo, Y. J. Yun, S. Park, Y. C. Shin, S. G. Ko, "Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling," Mediators of Inflammation, vol. 2014,DOI: 10.1155/2014/492173, 2014.

[27] T. C. Chou, "Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies," Pharmacological Reviews, vol. 58 no. 3, pp. 621-681, DOI: 10.1124/pr.58.3.10, 2006.

[28] J. M. Nabholtz, D. M. Reese, M. A. Lindsay, A. Riva, "Docetaxel in the treatment of breast cancer: an update on recent studies," Seminars in Oncology, vol. 29, pp. 28-34, DOI: 10.1053/sonc.2002.34262, 2002.

[29] A. B. Nair, S. Jacob, "A simple practice guide for dose conversion between animals and human," Journal of basic and clinical pharmacy, vol. 7 no. 2, pp. 27-31, DOI: 10.4103/0976-0105.177703, 2016.

[30] I. Mahmood, "Theoretical versus empirical allometry: facts behind theories application to pharmacokinetics," Journal of Pharmaceutical Sciences, vol. 99 no. 7, pp. 2927-2933, DOI: 10.1002/jps.22073, 2010.

[31] Z. Maciorowski, J. Klijanienko, E. Padoy, V. Mosseri, A. Fourquet, S. Chevillard, A. K. El-Naggar, P. Vielh, "Comparative image and flow cytometric TUNEL analysis of fine needle samples of breast carcinoma," Cytometry, vol. 46 no. 3, pp. 150-156, DOI: 10.1002/cyto.1099, 2001.

[32] I. Shukla, L. Azmi, C. V. Rao, T. Jawaid, M. Kamal, A. S. Awaad, S. I. Alqasoumi, O. A. Alkhamees, S. M. Alsanad, "Hepatoprotective activity of depsidone enriched _Cladonia rangiferina_ extract against alcohol-induced hepatotoxicity targeting cytochrome P450 2E1 induced oxidative damage," Saudi Pharmaceutical Journal, vol. 28 no. 4, pp. 519-527, DOI: 10.1016/j.jsps.2020.03.003, 2020.

[33] H. Hossein-Nejad-Ariani, E. Althagafi, K. Kaur, "Small peptide ligands for targeting EGFR in triple negative breast cancer cells," Scientific Reports, vol. 9 no. 1,DOI: 10.1038/s41598-019-38574-y, 2019.

[34] S. Galban, A. A. Apfelbaum, C. Espinoza, K. Heist, H. Haley, K. Bedi, M. Ljungman, C. J. Galban, G. D. Luker, M. V. Dort, B. D. Ross, "A bifunctional MAPK/PI3K antagonist for inhibition of tumor growth and metastasis," Molecular Cancer Therapeutics, vol. 16 no. 11, pp. 2340-2350, DOI: 10.1158/1535-7163.MCT-17-0207, 2017.

[35] J. M. Giltnane, J. M. Balko, "Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer," Discovery Medicine, vol. 17 no. 95, pp. 275-283, 2014.

[36] Y. H. Kuo, E. I. Chiang, C. Y. Chao, R. L. Rodriguez, P. Y. Chou, S. Y. Tsai, M. H. Pai, F. Y. Tang, "Dual inhibition of key proliferation signaling pathways in triple-negative breast cancer cells by a novel derivative of Taiwanin A," Molecular Cancer Therapeutics, vol. 16 no. 3, pp. 480-493, DOI: 10.1158/1535-7163.MCT-16-0011, 2017.

[37] J. J. Qin, L. Yan, J. Zhang, W. D. Zhang, "STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review," Journal of Experimental & Clinical Cancer Research, vol. 38 no. 1,DOI: 10.1186/s13046-019-1206-z, 2019.

[38] K. A. Nyrop, A. M. Deal, K. E. Reeder-Hayes, S. S. Shachar, B. B. Reeve, E. Basch, S. K. Choi, J. T. Lee, W. A. Wood, C. K. Anders, L. A. Carey, E. C. Dees, T. A. Jolly, G. G. Kimmick, M. S. Karuturi, R. E. Reinbolt, J. E. C. Speca, H. B. Muss, "Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: current clinical practice," Cancer, vol. 125 no. 17, pp. 2945-2954, DOI: 10.1002/cncr.32175, 2019.

[39] P. Rochigneux, N. Schleinitz, M. Ebbo, M. Aymonier, B. Pourroy, R. Boissier, S. Salas, J. L. Deville, "Acute myositis," Anti-Cancer Drugs, vol. 29 no. 5, pp. 477-481, DOI: 10.1097/CAD.0000000000000620, 2018.

[40] M. Ruiz-Borrego, B. Jimenez, S. Antolín, J. A. García-Saenz, J. Corral, Y. Jerez, J. Trigo, A. Urruticoechea, H. Colom, N. Gonzalo, C. Muñoz, S. Benito, R. Caballero, S. Bezares, E. Carrasco, F. Rojo, M. Martín, "A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study," Investigational New Drugs, vol. 37 no. 1, pp. 98-108, DOI: 10.1007/s10637-018-0614-9, 2019.

[41] C. Y. Liu, K. F. Chen, T. I. Chao, P. Y. Chu, C. T. Huang, T. T. Huang, H. P. Yang, W. L. Wang, C. H. Lee, K. Y. Lau, W. C. Tsai, J. C. Su, C. Y. Wu, M. H. Chen, C. W. Shiau, L. M. Tseng, "Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells," Journal of Molecular Medicine (Berlin, Germany), vol. 95 no. 9, pp. 965-975, DOI: 10.1007/s00109-017-1549-x, 2017.

[42] S. Hema Iswarya, M. Doble, "Potential synergism of natural products in the treatment of cancer," Phytotherapy Research, vol. 20 no. 4, pp. 239-249, DOI: 10.1002/ptr.1841, 2006.

[43] M. Royt, S. Mukherjee, R. Sarkar, J. Biswas, "Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NF-kappaB and HDAC in breast cancer," Therapeutic Delivery, vol. 2 no. 10, pp. 1275-1293, DOI: 10.4155/tde.11.97, 2011.

[44] Y. Yu, Q. Zhou, Y. Hang, X. Bu, W. Jia, "Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells," Cancer, vol. 109 no. 11, pp. 2374-2382, DOI: 10.1002/cncr.22659, 2007.

[45] N. Gyemant, M. Tanaka, S. Antus, J. Hohmann, O. Csuka, L. Mandoky, J. Molnar, "In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells," In Vivo, vol. 19 no. 2, pp. 367-374, 2005.

[46] A. C. Palmer, C. Chidley, P. K. Sorger, "A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity," eLife, vol. 8,DOI: 10.7554/eLife.50036, 2019.

[47] J. M. Nabholtz, N. Chalabi, N. Radosevic-Robin, M. M. Dauplat, M. A. Mouret-Reynier, I. van Praagh, V. Servent, J. P. Jacquin, K. E. Benmammar, S. Kullab, M. R. K. Bahadoor, F. Kwiatkowski, A. Cayre, C. Abrial, X. Durando, Y. J. Bignon, P. Chollet, F. Penault-Llorca, "Multicentric neoadjuvant pilot phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer," International Journal of Cancer, vol. 138 no. 9, pp. 2274-2280, DOI: 10.1002/ijc.29952, 2016.

[48] F. Zhou, C. C. Zhou, "Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough," Chinese Journal of Cancer, vol. 34 no. 7, pp. 310-319, DOI: 10.1186/s40880-015-0036-4, 2015.

[49] A. El Guerrab, M. Bamdad, F. Kwiatkowski, Y. J. Bignon, F. Penault-Llorca, C. Aubel, "Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer," Oncotarget, vol. 7 no. 45, pp. 73618-73637, DOI: 10.18632/oncotarget.12037, 2016.

[50] P. S. Mundi, J. Sachdev, C. McCourt, K. Kalinsky, "AKT in cancer: new molecular insights and advances in drug development," British Journal of Clinical Pharmacology, vol. 82 no. 4, pp. 943-956, DOI: 10.1111/bcp.13021, 2016.

[51] M. Kohno, J. Pouyssegur, "Targeting the ERK signaling pathway in cancer therapy," Annals of Medicine, vol. 38 no. 3, pp. 200-211, DOI: 10.1080/07853890600551037, 2006.

[52] M. Z. Kamran, P. Patil, R. P. Gude, "Role of STAT3 in cancer metastasis and translational advances," BioMed Research International, vol. 2013,DOI: 10.1155/2013/421821, 2013.

[53] R. L. B. Costa, H. S. Han, W. J. Gradishar, "Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review," Breast Cancer Research and Treatment, vol. 169 no. 3, pp. 397-406, DOI: 10.1007/s10549-018-4697-y, 2018.

[54] J. Huang, Q. Luo, Y. Xiao, H. Li, L. Kong, G. Ren, "The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer," Oncotarget, vol. 8 no. 64, pp. 108249-108260, DOI: 10.18632/oncotarget.22604, 2017.

[55] D. S. Hirsch, Y. Shen, W. J. Wu, "Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc 42," Cancer Research, vol. 66 no. 7, pp. 3523-3530, DOI: 10.1158/0008-5472.CAN-05-1547, 2006.

[56] L. Li, P. E. Shaw, "Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines," The Journal of Biological Chemistry, vol. 277 no. 20, pp. 17397-17405, DOI: 10.1074/jbc.M109962200, 2002.

[57] A. R. Tan, X. Yang, S. M. Hewitt, A. Berman, E. R. Lepper, A. Sparreboom, A. L. Parr, W. D. Figg, C. Chow, S. M. Steinberg, S. L. Bacharach, M. Whatley, J. A. Carrasquillo, J. S. Brahim, S. A. Ettenberg, S. Lipkowitz, S. M. Swain, "Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor," Journal of Clinical Oncology, vol. 22 no. 15, pp. 3080-3090, DOI: 10.1200/JCO.2004.08.189, 2004.

[58] T. Li, Y. H. Ling, R. Perez-Soler, "RETRACTED: tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene," Journal of Thoracic Oncology, vol. 3 no. 6, pp. 643-647, DOI: 10.1097/JTO.0b013e3181753b24, 2008.

[59] J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascón, V. Guillém, S. González, S. Sauleda, I. Marimón, J. M. Tabernero, M. T. Koehler, F. Rojo, "Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer," Journal of Clinical Oncology, vol. 23 no. 23, pp. 5323-5333, DOI: 10.1200/JCO.2005.08.326, 2005.